CRISPR-Cas13forRNA-TargetedAntivirals

Why It Matters

Viral pandemics and endemic infections (e.g., influenza, HIV, future novel viruses) pose immense global health threats, causing millions of deaths and trillions in economic losses annually. RNA-targeted CRISPR-Cas13 could provide a rapid-response, adaptable antiviral platform to combat current and emerging viral threats, potentially preventing future pandemics. Biotech companies like Mammoth Biosciences and other gene therapy developers would gain a significant advantage, while traditional pharmaceutical companies focused on small-molecule antivirals might face increased competition. Key technical challenges include efficient and safe delivery of the Cas13 system to target cells in vivo, and avoiding off-target RNA cleavage; regulatory pathways for RNA-editing therapies are still evolving. Initial clinical trials for specific viral diseases could begin in 5-10 years, with widespread therapeutic use in 15-20 years. The US, Europe, and China are significant players in CRISPR research. A second-order consequence could be a shift towards 'on-demand' programmable therapeutics, where treatments are designed and deployed rapidly in response to new pathogen outbreaks.